Reply
Barret Rush, Keith R. Walley, Leo Anthony Celi, Neil Rajoriya, Mayur Brahmania – 18 September 2017
Necessity of More Sensitivity Analyses and Interpretations From Public Health Perspectives
Vasveebye Sonoo, Jay V. Kumar, Xibei Liu, Johnson Ukken, Mary Froehlich, Ji Won Yoo – 18 September 2017
Validation of artificial neural networks as a methodology for donor‐recipient matching for liver transplantation
María Dolores Ayllón, Rubén Ciria, Manuel Cruz‐Ramírez, María Pérez‐Ortiz, Irene Gómez, Roberto Valente, John O'Grady, Manuel de la Mata, César Hervás‐Martínez, Nigel D. Heaton, Javier Briceño – 16 September 2017 – In 2014, we reported a model for donor‐recipient (D‐R) matching in liver transplantation (LT) based on artificial neural networks (ANNs) from a Spanish multicenter study (Model for Allocation of Donor and Recipient in España [MADR‐E]). The aim is to test the ANN‐based methodology in a different European health care system in order to validate it.
The reality of de novo malignancy: Sadly, not fake news
Manhal Izzy, Kymberly D. Watt – 16 September 2017
Graft‐infiltrating PD‐L1hi cross‐dressed dendritic cells regulate antidonor T cell responses in mouse liver transplant tolerance
Yoshihiro Ono, Angelica Perez‐Gutierrez, Toshimasa Nakao, Helong Dai, Geoffrey Camirand, Osamu Yoshida, Shinichiro Yokota, Donna Beer Stolz, Mark A. Ross, Adrian E. Morelli, David A. Geller, Angus W. Thomson – 16 September 2017 – Although a key role of cross‐dressing has been established in immunity to viral infection and more recently in the instigation of transplant rejection, its role in tolerance is unclear.
The interplay of type I and type II interferons in murine autoimmune cholangitis as a basis for sex‐biased autoimmunity
Heekyong R. Bae, Deborah L. Hodge, Guo‐Xiang Yang, Patrick S.C. Leung, Sathi Babu Chodisetti, Julio C. Valencia, Michael Sanford, John M. Fenimore, Ziaur S.M. Rahman, Koichi Tsuneyama, Gary L. Norman, M. Eric Gershwin, Howard A. Young – 16 September 2017 – We have reported on a murine model of autoimmune cholangitis, generated by altering the AU‐rich element (ARE) by deletion of the interferon gamma (IFN‐γ) 3' untranslated region (coined ARE‐Del−/−), that has striking similarities to human primary biliary cholangitis (PBC) with female predominance.
Solving doubts about L‐ornithine L‐aspartate for overt hepatic encephalopathy: Whom and how to treat
Piero Amodio, Javier Ampuero – 16 September 2017
Late hepatitis B reactivation following direct‐acting antiviral–based treatment of recurrent hepatitis C in an anti‐HBc–positive liver transplant recipient
Julien Vionnet, Manuel Pascual, Barbara Testoni, Christophe Combet, Sébastien Godat, Sandrine Vijgen, Vincent Aubert, Laura Rubbia‐Brandt, Fabien Zoulim, Darius Moradpour – 16 September 2017 – Direct‐acting antivirals (DAAs) have changed the landscape of hepatitis C virus (HCV) treatment, but chronic hepatitis C (CHC) remains a leading indication for liver transplantation (LT). Hepatitis B virus (HBV) reactivation has been reported in HBV‐HCV‐coinfected patients treated with DAAs.
Late hepatitis B reactivation following direct‐acting antiviral–based treatment of recurrent hepatitis C in an anti‐HBc–positive liver transplant recipient
Julien Vionnet, Manuel Pascual, Barbara Testoni, Christophe Combet, Sébastien Godat, Sandrine Vijgen, Vincent Aubert, Laura Rubbia‐Brandt, Fabien Zoulim, Darius Moradpour – 16 September 2017 – Direct‐acting antivirals (DAAs) have changed the landscape of hepatitis C virus (HCV) treatment, but chronic hepatitis C (CHC) remains a leading indication for liver transplantation (LT). Hepatitis B virus (HBV) reactivation has been reported in HBV‐HCV‐coinfected patients treated with DAAs.
Reply
Lisa B. VanWagner, Hongyan Ning, Maureen Whitsett, Josh Levitsky, Sarah Uttal, John T. Wilkins, Michael M. Abecassis, Daniela P. Ladner, Anton I. Skaro, Donald M. Lloyd‐Jones – 16 September 2017